Fellow will join RIDC CIBFar to work in the development of antiviral molecules by purifying SARS-CoV-2 proteins and designing specific ligands and inhibitors using methodologies such as fragment screening e co-crystallization
Partnering with CNPEM, CIBFar researchers used the protein crystallography beamline to analyze more than 200 protein crystals from the novel coronavirus as they were exposed to tiny fragments of widely used drugs. If a compound fits perfectly into a target protein, its action can be blocked in the virus
Synthetic compounds and molecules derived from natural products belonging to Brazil’s biodiversity are being screened by teams at the Center for Innovation in Biodiversity and Drug Discovery.
Initiative supported by FAPESP, USP, UNICAMP and global partners sets out to discover new molecules against tropical parasitic diseases. Its aim is to develop effective and affordable drugs.
Glaucius Oliva speaks at FAPESP Week London about the line of work of the Center for Research and Innovation in Biodiversity and Drug Discovery and how the UK collaboration helps developing structural biology in Brazil.
Few novel drugs have been developed to treat neglected diseases in recent decades, Brazilian researchers warn.
The compound called GA-Hecate also acts on bacteria, fungi and cancer cells and will be tested against Zika and yellow fever viruses.
Molecule designed by the Center for Research and Innovation in Biodiversity and Drug Discovery killed malaria parasite in mice and in vitro culture.